Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with burkitt lymphoma/leukemia [4]

Pediatric Blood and Cancer

Volumn 50, Issue 1, 2008, Pages 189-

  Borinstein, Scott C ^a,b   Hawkins, Douglas S ^a   Xu, Min ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CALCITONIN; CYCLOPHOSPHAMIDE; FUROSEMIDE; PREDNISONE; RASBURICASE; VINCRISTINE;

BURKITT LYMPHOMA; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYTIC ANEMIA; HUMAN; HYPERCALCEMIA; HYPERURICEMIA; LABORATORY TEST; LETTER; LEUKEMIA; METHEMOGLOBINEMIA; PRIORITY JOURNAL;

ADOLESCENT; ANEMIA, HEMOLYTIC; BURKITT LYMPHOMA; GLYCOGEN STORAGE DISEASE TYPE I; HUMANS; HYPERURICEMIA; MALE; METHEMOGLOBINEMIA; RECOMBINANT PROTEINS; URATE OXIDASE;

EID: 36849050185     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21193     Document Type: Letter

References (3)

1. Insert P. 2005; Elitek (rasburicase) Package Insert. Sanofi-Synthelabo http://products.sanofi-aventis.us/elitek/elitek.html
2. Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: Report of an international compassionate use study. Cancer 2003;98:1048-1054.
3. Browning LA, Kruse JA. Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother 2005;39:1932-1935.